In the case of siRNAs, researchers have explored their potential in targeting critical genes in cancer, such as the use of siRNAs against the BCR-ABL fusion gene in chronic myeloid leukemia and siRNAs targeting KRAS mutations in pancreatic cancer. Here, KRAS is linked to pancreatic neoplasm.